Le informazioni sugli articoli di fonte ISI sono coperte da copyright

Per ulteriori informazioni selezionare i riferimenti di interesse.

1. Emilien, G; Durlach, C; Aveaux, D; Maloteaux, JM
   Dopamine D-3 agonists
   EXPERT OPINION ON THERAPEUTIC PATENTS
   
   G. Emilien et al., "Dopamine D-3 agonists", EXPERT OP T, 11(11), 2001, pp. 1713-1728
2. Robinet, EA; Geurts, M; Maloteaux, JM; Pauwels, PJ
   Chronic treatment with certain antipsychotic drugs preserves upregulation of regulator of G-protein signalling 2 mRNA in rat striatum as opposed to c-fos mRNA
   NEUROSCIENCE LETTERS
   
   E.A. Robinet et al., "Chronic treatment with certain antipsychotic drugs preserves upregulation of regulator of G-protein signalling 2 mRNA in rat striatum as opposed to c-fos mRNA", NEUROSCI L, 307(1), 2001, pp. 45-48
3. Emilien, G; Misteli, C; Aveaux, D; Maloteaux, JM
   Life after sequencing
   TRENDS IN BIOTECHNOLOGY
   
   G. Emilien et al., "Life after sequencing", TRENDS BIOT, 19(7), 2001, pp. 246-246
4. Page, G; Peeters, M; Najimi, M; Maloteaux, JM; Hermans, E
   Modulation of the neuronal dopamine transporter activity by the metabotropic glutamate receptor mGluR5 in rat striatal synaptosomes through phosphorylation mediated processes
   JOURNAL OF NEUROCHEMISTRY
   
   G. Page et al., "Modulation of the neuronal dopamine transporter activity by the metabotropic glutamate receptor mGluR5 in rat striatal synaptosomes through phosphorylation mediated processes", J NEUROCHEM, 76(5), 2001, pp. 1282-1290
5. Emilien, G; Ponchon, M; Caldas, C; Isacson, O; Maloteaux, JM
   Impact of genomics on drug discovery and clinical medicine
   QJM-MONTHLY JOURNAL OF THE ASSOCIATION OF PHYSICIANS
   
   G. Emilien et al., "Impact of genomics on drug discovery and clinical medicine", QJM-MON J A, 93(7), 2000, pp. 391-423
6. Emilien, G; van Meurs, W; Maloteaux, JM
   The dose-response relationship in Phase I clinical trials and beyond: use,meaning, and assessment
   PHARMACOLOGY & THERAPEUTICS
   
   G. Emilien et al., "The dose-response relationship in Phase I clinical trials and beyond: use,meaning, and assessment", PHARM THERA, 88(1), 2000, pp. 33-58
7. Emilien, G; Maloteaux, JM; Penasse, C; Goodeve, A; Casimir, C
   Haemophilias: advances towards genetic engineering replacement therapy
   CLINICAL AND LABORATORY HAEMATOLOGY
   
   G. Emilien et al., "Haemophilias: advances towards genetic engineering replacement therapy", CLIN LAB H, 22(6), 2000, pp. 313-323
8. Noel, F; Geurts, M; Maloteaux, JM
   Selective destruction of nigrostriatal dopaminergic neurons does not alter[H-3]-ryanodine binding in rat striatum
   BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH
   
   F. Noel et al., "Selective destruction of nigrostriatal dopaminergic neurons does not alter[H-3]-ryanodine binding in rat striatum", BRAZ J MED, 33(2), 2000, pp. 237-240
9. Page, G; Peeters, M; Maloteaux, JM; Hermans, E
   Increased dopamine uptake in striatal synaptosomes after treatment of ratswith amantadine
   EUROPEAN JOURNAL OF PHARMACOLOGY
   
   G. Page et al., "Increased dopamine uptake in striatal synaptosomes after treatment of ratswith amantadine", EUR J PHARM, 403(1-2), 2000, pp. 75-80
10. Emilien, G; Beyreuther, K; Masters, CL; Maloteaux, JM
    Prospects for pharmacological intervention in Alzheimer disease
    ARCHIVES OF NEUROLOGY
    
    G. Emilien et al., "Prospects for pharmacological intervention in Alzheimer disease", ARCH NEUROL, 57(4), 2000, pp. 454-459
11. Emilien, G; Maloteaux, JM; Beyreuther, K; Masters, CL
    Alzheimer disease - Mouse models pave the way for therapeutic opportunities
    ARCHIVES OF NEUROLOGY
    
    G. Emilien et al., "Alzheimer disease - Mouse models pave the way for therapeutic opportunities", ARCH NEUROL, 57(2), 2000, pp. 176-181
12. Emilien, G; Maloteaux, JM
    Circadian system and sleep anomaly in depression
    IRISH JOURNAL OF PSYCHOLOGICAL MEDICINE
    
    G. Emilien e J.M. Maloteaux, "Circadian system and sleep anomaly in depression", IRIS J PS M, 16(1), 1999, pp. 18-23
13. Emilien, G; Maloteaux, JM; Geurts, M; Hoogenberg, K; Cragg, S
    Dopamine receptors - physiological understanding to therapeutic intervention potential
    PHARMACOLOGY & THERAPEUTICS
    
    G. Emilien et al., "Dopamine receptors - physiological understanding to therapeutic intervention potential", PHARM THERA, 84(2), 1999, pp. 133-156
14. Emilien, G; Maloteaux, JM; Ponchon, M
    Pharmacological management of diabetes: Recent progress and future perspective in daily drug treatment
    PHARMACOLOGY & THERAPEUTICS
    
    G. Emilien et al., "Pharmacological management of diabetes: Recent progress and future perspective in daily drug treatment", PHARM THERA, 81(1), 1999, pp. 37-51
15. Geurts, M; Hermans, E; Maloteaux, JM
    Assessment of striatal D1 and D2 dopamine receptor-G protein coupling by agonist-induced [S-35]GTP gamma S binding
    LIFE SCIENCES
    
    M. Geurts et al., "Assessment of striatal D1 and D2 dopamine receptor-G protein coupling by agonist-induced [S-35]GTP gamma S binding", LIFE SCI, 65(16), 1999, pp. 1633-1645
16. Geurts, M; Hermans, E; Maloteaux, JM
    Enhanced striatal dopamine D-2 receptor-induced [S-35]GTP gamma S binding after haloperidol treatment
    EUROPEAN JOURNAL OF PHARMACOLOGY
    
    M. Geurts et al., "Enhanced striatal dopamine D-2 receptor-induced [S-35]GTP gamma S binding after haloperidol treatment", EUR J PHARM, 382(2), 1999, pp. 119-127
17. Geurts, M; Hermans, E; Cumps, J; Maloteaux, JM
    Dopamine receptor-modulated [S-35]GTP gamma S binding in striatum of 6-hydroxydopamine-lesioned rats
    BRAIN RESEARCH
    
    M. Geurts et al., "Dopamine receptor-modulated [S-35]GTP gamma S binding in striatum of 6-hydroxydopamine-lesioned rats", BRAIN RES, 841(1-2), 1999, pp. 135-142
18. Hantson, P; Leonard, F; Maloteaux, JM; Mahieu, P
    How epileptogenic are the recent antibiotics?
    ACTA CLINICA BELGICA
    
    P. Hantson et al., "How epileptogenic are the recent antibiotics?", ACT CLIN B, 54(2), 1999, pp. 80-87
19. EMILIEN G; MALOTEAUX JM
    PHARMACOLOGICAL MANAGEMENT OF EPILEPSY - MECHANISM OF ACTION, PHARMACOKINETIC DRUG-INTERACTIONS, AND NEW DRUG DISCOVERY POSSIBILITIES
    International journal of clinical pharmacology and therapeutics
    
    G. Emilien e J.M. Maloteaux, "PHARMACOLOGICAL MANAGEMENT OF EPILEPSY - MECHANISM OF ACTION, PHARMACOKINETIC DRUG-INTERACTIONS, AND NEW DRUG DISCOVERY POSSIBILITIES", International journal of clinical pharmacology and therapeutics, 36(4), 1998, pp. 181-194
20. EMILIEN G; MALOTEAUX JM; SEGHERS A; CHARLES G
    USE OF A PLACEBO IN CLINICAL-TRIALS
    European psychiatry
    
    G. Emilien et al., "USE OF A PLACEBO IN CLINICAL-TRIALS", European psychiatry, 13(5), 1998, pp. 254-263
21. HERMANS E; MALOTEAUX JM
    MECHANISMS OF REGULATION OF NEUROTENSIN RECEPTORS
    Pharmacology & therapeutics (Oxford)
    
    E. Hermans e J.M. Maloteaux, "MECHANISMS OF REGULATION OF NEUROTENSIN RECEPTORS", Pharmacology & therapeutics (Oxford), 79(2), 1998, pp. 89-104
22. EMILIEN G; MALOTEAUX JM
    CURRENT THERAPEUTIC USES AND POTENTIAL OF BETA-ADRENOCEPTOR AGONISTS AND ANTAGONISTS
    European Journal of Clinical Pharmacology
    
    G. Emilien e J.M. Maloteaux, "CURRENT THERAPEUTIC USES AND POTENTIAL OF BETA-ADRENOCEPTOR AGONISTS AND ANTAGONISTS", European Journal of Clinical Pharmacology, 53(6), 1998, pp. 389-404
23. GEURTS M; HERMANS E; MALOTEAUX JM
    DOPAMINE RECEPTOR-MODULATED [S-35] GTP-GAMMA-S BINDING IN STRIATUM OF6-HYDROXYDOPAMINE-LESIONED RATS
    Naunyn-Schmiedeberg's archives of pharmacology
    
    M. Geurts et al., "DOPAMINE RECEPTOR-MODULATED [S-35] GTP-GAMMA-S BINDING IN STRIATUM OF6-HYDROXYDOPAMINE-LESIONED RATS", Naunyn-Schmiedeberg's archives of pharmacology, 358(1), 1998, pp. 729-729
24. HERMANS E; GEURTS M; MALOTEAUX JM
    CHARACTERIZATION OF THE FUNCTIONAL COUPLING OF THE NEUROTENSIN AND MUSCARINIC RECEPTORS USING AGONISTS-INDUCED [S-35] GTP-GAMMA-S BINDING ASSAY
    Acta neurologica belgica
    
    E. Hermans et al., "CHARACTERIZATION OF THE FUNCTIONAL COUPLING OF THE NEUROTENSIN AND MUSCARINIC RECEPTORS USING AGONISTS-INDUCED [S-35] GTP-GAMMA-S BINDING ASSAY", Acta neurologica belgica, 97(1), 1997, pp. 58-58
25. HERMANS E; VANISBERG MA; GEURTS M; MALOTEAUX JM
    DOWN-REGULATION OF NEUROTENSIN RECEPTORS AFTER LIGAND-INDUCED INTERNALIZATION IN RAT PRIMARY CULTURED NEURONS
    Neurochemistry international
    
    E. Hermans et al., "DOWN-REGULATION OF NEUROTENSIN RECEPTORS AFTER LIGAND-INDUCED INTERNALIZATION IN RAT PRIMARY CULTURED NEURONS", Neurochemistry international, 31(2), 1997, pp. 291-299
26. HERMANS E; GEURTS M; MALOTEAUX JM
    AGONIST AND ANTAGONIST MODULATION OF [S-35] GTP-GAMMA-S BINDING IN TRANSFECTED CHO CELLS EXPRESSING THE NEUROTENSIN RECEPTOR
    British Journal of Pharmacology
    
    E. Hermans et al., "AGONIST AND ANTAGONIST MODULATION OF [S-35] GTP-GAMMA-S BINDING IN TRANSFECTED CHO CELLS EXPRESSING THE NEUROTENSIN RECEPTOR", British Journal of Pharmacology, 121(8), 1997, pp. 1817-1823
27. JEANJEAN AP; LATERRE EC; MALOTEAUX JM
    NEUROLEPTIC BINDING TO SIGMA-RECEPTORS - POSSIBLE INVOLVEMENT IN NEUROLEPTIC-INDUCED ACUTE DYSTONIA
    Biological psychiatry
    
    A.P. Jeanjean et al., "NEUROLEPTIC BINDING TO SIGMA-RECEPTORS - POSSIBLE INVOLVEMENT IN NEUROLEPTIC-INDUCED ACUTE DYSTONIA", Biological psychiatry, 41(10), 1997, pp. 1010-1019
28. EMILIEN G; MALOTEAUX JM; SEGHERS A; CHARLES G
    LITHIUM COMPARED TO VALPROIC ACID AND CARBAMAZEPINE IN THE TREATMENT OF MANIA - A STATISTICAL METAANALYSIS
    European neuropsychopharmacology
    
    G. Emilien et al., "LITHIUM COMPARED TO VALPROIC ACID AND CARBAMAZEPINE IN THE TREATMENT OF MANIA - A STATISTICAL METAANALYSIS", European neuropsychopharmacology, 6(3), 1996, pp. 245-252
29. EMILIEN G; MALOTEAUX JM
    LITHIUM NEUROTOXICITY AT LOW THERAPEUTIC DOSES HYPOTHESES FOR CAUSES AND MECHANISM OF ACTION FOLLOWING A RETROSPECTIVE ANALYSIS OF PUBLISHED CASE-REPORTS
    Acta neurologica belgica
    
    G. Emilien e J.M. Maloteaux, "LITHIUM NEUROTOXICITY AT LOW THERAPEUTIC DOSES HYPOTHESES FOR CAUSES AND MECHANISM OF ACTION FOLLOWING A RETROSPECTIVE ANALYSIS OF PUBLISHED CASE-REPORTS", Acta neurologica belgica, 96(4), 1996, pp. 281-293
30. LACOMBLEZ L; BENSIMON G; LEIGH PN; GUILLET P; POWE L; DURRLEMAN S; DELUMEAU JC; MEININGER V; PUECH AJ; WHITEHEAD J; ASSELAIN B; CESARO P; LARREY D; ROSSOR M; ZIMMERMAN HJ; SALZMAN P; DOPPLER V; LLOYD CM; MALOTEAUX JM; DELWAIDE C; LATERRE EC; BOUCHARD JP; DUQUETTE P; GIRARD M; MASSE C; EISEN A; BLIN O; AZULAY JP; BILLETURC F; POUGET J; BOUCHE P; CAMU M; CARLANDER B; BILLIARD M; CLANET M; ANGIBAUD G; ARNEBES MC; BENAZET M; COURATIER P; VALLAT JM; DESNUELLE C; LAGUENY A; ELLIE E; DIB M; ROZIER A; SALACHAS F; VIADER F; DELAUNAY D; DENGLER R; KUTHER G; TROGER M; LUDOLPH A; BACHUS R; GERICKE C; PRZUNTEK H; LANGKAFEL M; SCHIMRIGK K; JOST WH; OSTERHAGE J; PRUDLO J; MORA J; CHAVERRI D; SAENZ E; JEFFERSON D; ORPE V; LANE RJM; ORRELL RW; BARBIE T; MITCHELL JD; KILSHAW J; PALL HS; GOODWIN M; SCHADY W; DUNCAN S; MOORE C; RICHARDS C; SHAW PJ; CHARI G; PICKERING B; SWASH M; HARATI Y; GOOCH CL; ECHOLS CW; MILLER RG; GELINAS DF; QUIEN A; MUNSTAT TL; THORNELL B; ROTHSTEIN JD; CLAWSON L; SUFIT R; CASEY P; DELUMEAU J; TRUFFINET P; DEBOVE C; ENFRIN P; HAMPTON G; MULLER F; NGUYEN T; ROTHFUSS D; SENECHAL A; SHU C; LESWELL P; WHITWORTH P; DEBOE M; DEBRUYCKERE M; FISHER W; KONIG M; VERDUGO L; DELOSTERREROS MS; DEAKIN D; GIGUERE M; ADAIR K; FRANCO M; SKARINSKY D; WEXLER M; PIZZATO M; LEDOUX L; CAMPAGNES E; HARTNETT M; BASTIEN P; BEJUIT R; KIM Y; LELANN L; LEROY F; PAPILLON C; ORVOENFRIJA E
    A CONFIRMATORY DOSE-RANGING STUDY OF RILUZOLE IN ALS
    Neurology
    
    L. Lacomblez et al., "A CONFIRMATORY DOSE-RANGING STUDY OF RILUZOLE IN ALS", Neurology, 47(6), 1996, pp. 242-250
31. MILLER RG; BOUCHARD JP; DUQUETTE P; EISEN A; GELINAS DF; HARATI Y; MUNSAT TL; POWE L; ROTHSTEIN J; SALZMAN P; SUFIT RL; GUILLET P; BENSIMON G; DELUMEAU JC; DURRLEMAN S; LACOMBLEZ L; LEIGH PN; MEININGER V; MALOTEAUX JM; DELWAIDE C; GIRARD M; MASSE C; BLIN O; AZULAY JP; BILLETURC F; POUGET J; BOUCHE P; CAMU W; CARLANDER B; CLANET M; ANGIBAUD G; ARNEBES MC; BENAZET M; COURATIER P; DESNUELLE C; LAGUENY A; ELLIE E; DIB M; ROZIER A; SALACHAS F; VIADER F; DELAUNAY D; DENGLER R; GUTHER G; TROGER M; LUDOLPH A; BACHUS R; GERICKE C; PRZUNTEK H; LANGKAFEL M; SCHIMRIGK K; JOST WH; OSTERHAGE J; PRUDLO J; MORA J; CHAVERRI D; SAENZ E; JEFFERSON D; ORPE V; LANE RJM; ORRELL RW; LLOYD CM; BARBIE T; MITCHELL JD; KILSHAW J; PALL HS; GOODWIN M; SCHADY W; DUNCAN S; MOORE C; RICKARDS C; SHAW PJ; PICKERING CB; SWASH M; GOOCH CL; ECHOLS CW; QUIEN A; THORNELL B; ROTHSTEIN JD; CLAWSON L; SUFIT R; CASEY P
    CLINICAL-TRIALS OF RILUZOLE IN PATIENTS WITH ALS
    Neurology
    
    R.G. Miller et al., "CLINICAL-TRIALS OF RILUZOLE IN PATIENTS WITH ALS", Neurology, 47(4), 1996, pp. 86-90
32. HERMANS E; OCTAVE JN; MALOTEAUX JM
    INTERACTION OF THE COOH-TERMINAL DOMAIN OF THE NEUROTENSIN RECEPTOR WITH A G-PROTEIN DOES NOT CONTROL THE PHOSPHOLIPASE-C ACTIVATION BUT ISINVOLVED IN THE AGONIST-INDUCED INTERNALIZATION
    Molecular pharmacology
    
    E. Hermans et al., "INTERACTION OF THE COOH-TERMINAL DOMAIN OF THE NEUROTENSIN RECEPTOR WITH A G-PROTEIN DOES NOT CONTROL THE PHOSPHOLIPASE-C ACTIVATION BUT ISINVOLVED IN THE AGONIST-INDUCED INTERNALIZATION", Molecular pharmacology, 49(2), 1996, pp. 365-372
33. HERMANS E; MALOTEAUX JM
    DESENSITIZATION OF NEUROTENSIN-INDUCED PHOSPHOINOSITIDE HYDROLYSIS INTRANSFECTED CHO CELLS
    Biochemical pharmacology
    
    E. Hermans e J.M. Maloteaux, "DESENSITIZATION OF NEUROTENSIN-INDUCED PHOSPHOINOSITIDE HYDROLYSIS INTRANSFECTED CHO CELLS", Biochemical pharmacology, 51(12), 1996, pp. 1749-1752
34. SAM E; JEANJEAN AP; MALOTEAUX JM; VERBEKE N
    APOMORPHINE PHARMACOKINETICS IN PARKINSONISM AFTER INTRANASAL AND SUBCUTANEOUS APPLICATION
    European journal of drug metabolism and pharmacokinetics
    
    E. Sam et al., "APOMORPHINE PHARMACOKINETICS IN PARKINSONISM AFTER INTRANASAL AND SUBCUTANEOUS APPLICATION", European journal of drug metabolism and pharmacokinetics, 20(1), 1995, pp. 27-33
35. JEANJEAN AP; MOUSSAOUI SM; MALOTEAUX JM; LADURON PM
    INTERLEUKIN-1-BETA INDUCES LONG-TERM INCREASE OF AXONALLY TRANSPORTEDOPIATE RECEPTORS AND SUBSTANCE-P
    Neuroscience
    
    A.P. Jeanjean et al., "INTERLEUKIN-1-BETA INDUCES LONG-TERM INCREASE OF AXONALLY TRANSPORTEDOPIATE RECEPTORS AND SUBSTANCE-P", Neuroscience, 68(1), 1995, pp. 151-157
36. HOLEMANS S; FERON O; OCTAVE JN; MALOTEAUX JM
    INTERACTION OF FLUORESCEIN DERIVATIVES WITH GLIBENCLAMIDE BINDING-SITES IN RAT-BRAIN
    Neuroscience letters
    
    S. Holemans et al., "INTERACTION OF FLUORESCEIN DERIVATIVES WITH GLIBENCLAMIDE BINDING-SITES IN RAT-BRAIN", Neuroscience letters, 183(3), 1995, pp. 183-186
37. HERMANS E; GAILLY P; GILLIS JM; OCTAVE JN; MALOTEAUX JM
    LACK OF RAPID DESENSITIZATION OF CA2-INDUCED INTERNALIZATION( RESPONSES IN TRANSFECTED CHO CELLS EXPRESSING THE RAT NEUROTENSIN RECEPTOR DESPITE AGONIST)
    Journal of neurochemistry
    
    E. Hermans et al., "LACK OF RAPID DESENSITIZATION OF CA2-INDUCED INTERNALIZATION( RESPONSES IN TRANSFECTED CHO CELLS EXPRESSING THE RAT NEUROTENSIN RECEPTOR DESPITE AGONIST)", Journal of neurochemistry, 64(6), 1995, pp. 2518-2525
38. MALOTEAUX JM; LUABEYA MK; VANISBERG MA; JEANJEAN AP; BAUDHUIN P; SCHERMAN D; LADURON PM
    SUBCELLULAR-DISTRIBUTION OF RECEPTOR-SITES IN HUMAN BRAIN - DIFFERENTIATION BETWEEN HEAVY AND LIGHT STRUCTURES OF HIGH AND LOW-DENSITY
    Brain research
    
    J.M. Maloteaux et al., "SUBCELLULAR-DISTRIBUTION OF RECEPTOR-SITES IN HUMAN BRAIN - DIFFERENTIATION BETWEEN HEAVY AND LIGHT STRUCTURES OF HIGH AND LOW-DENSITY", Brain research, 687(1-2), 1995, pp. 155-166
39. EMILIEN G; MALOTEAUX JM; SEGHERS A; CHARLES G
    LITHIUM-THERAPY IN THE TREATMENT OF MANIC-DEPRESSIVE ILLNESS - PRESENT STATUS AND FUTURE PERSPECTIVES - A CRITICAL-REVIEW
    Archives internationales de pharmacodynamie et de therapie
    
    G. Emilien et al., "LITHIUM-THERAPY IN THE TREATMENT OF MANIC-DEPRESSIVE ILLNESS - PRESENT STATUS AND FUTURE PERSPECTIVES - A CRITICAL-REVIEW", Archives internationales de pharmacodynamie et de therapie, 330(3), 1995, pp. 251-278
40. LAMBERT DM; POUPAERT JH; MALOTEAUX JM; DUMONT P
    ANTICONVULSANT ACTIVITIES OF N-BENZYLOXYCARBONYLGLYCINE AFTER PARENTERAL ADMINISTRATION
    NeuroReport
    
    D.M. Lambert et al., "ANTICONVULSANT ACTIVITIES OF N-BENZYLOXYCARBONYLGLYCINE AFTER PARENTERAL ADMINISTRATION", NeuroReport, 5(7), 1994, pp. 777-780
41. JEANJEAN AP; MALOTEAUX JM; LADURON PM
    IL-1-BETA-LIKE FREUNDS-ADJUVANT ENHANCES AXONAL-TRANSPORT OF OPIATE RECEPTORS IN SENSORY NEURONS
    Neuroscience letters
    
    A.P. Jeanjean et al., "IL-1-BETA-LIKE FREUNDS-ADJUVANT ENHANCES AXONAL-TRANSPORT OF OPIATE RECEPTORS IN SENSORY NEURONS", Neuroscience letters, 177(1-2), 1994, pp. 75-78
42. LEVIVIER M; HOLEMANS S; TOGASAKI DM; MALOTEAUX JM; BROTCHI J; PRZEDBORSKI S
    QUANTITATIVE ASSESSMENT OF QUINOLINIC ACID-INDUCED STRIATAL TOXICITY IN RATS USING RADIOLIGAND BINDING ASSAYS
    Neurological research
    
    M. Levivier et al., "QUANTITATIVE ASSESSMENT OF QUINOLINIC ACID-INDUCED STRIATAL TOXICITY IN RATS USING RADIOLIGAND BINDING ASSAYS", Neurological research, 16(3), 1994, pp. 194-200
43. GAILLY P; HERMANS E; MALOTEAUX JM; OCTAVE JN; GILLIS JM
    NEUROTENSIN-INDUCED CALCIUM RESPONSE IN CHO CELLS EXPRESSING THE RAT NEUROTENSIN RECEPTOR - DEPLETION OF INTRACELLULAR STORES COUPLED TO CALCIUM-ENTRY
    Pflugers Archiv
    
    P. Gailly et al., "NEUROTENSIN-INDUCED CALCIUM RESPONSE IN CHO CELLS EXPRESSING THE RAT NEUROTENSIN RECEPTOR - DEPLETION OF INTRACELLULAR STORES COUPLED TO CALCIUM-ENTRY", Pflugers Archiv, 427(3-4), 1994, pp. 180000063-180000063
44. BENSIMON G; LACOMBLEZ L; MEININGER V; BOUCHE P; DELWAIDE C; COURATIER P; BLIN O; VIADER F; PEYROSTPAUL H; DAVID J; MALOTEAUX JM; HUGON J; LATERRE EC; RASCOL A; CLANET M; VALLAT JM; DUMAS A; SERRATRICE G; LECHEVALLIER B; PEUCH AJ; NGUYEN T; SHU C; BASTIEN P; PAPILLON C; DURRLEMAN S; LOUVEL E; GUILLET P; LEDOUX L; ORVOENFRIJA E; DIB M
    A CONTROLLED TRIAL OF RILUZOLE IN AMYOTROPHIC-LATERAL-SCLEROSIS
    The New England journal of medicine
    
    G. Bensimon et al., "A CONTROLLED TRIAL OF RILUZOLE IN AMYOTROPHIC-LATERAL-SCLEROSIS", The New England journal of medicine, 330(9), 1994, pp. 585-591
45. HOLEMANS S; JAVOYAGID F; AGID Y; DEPAERMENTIER F; LATERRE EC; MALOTEAUX JM
    SULFONYLUREA BINDING-SITES IN NORMAL HUMAN BRAIN AND IN PARKINSONS-DISEASE, PROGRESSIVE SUPRANUCLEAR PALSY AND HUNTINGTONS-DISEASE
    Brain research
    
    S. Holemans et al., "SULFONYLUREA BINDING-SITES IN NORMAL HUMAN BRAIN AND IN PARKINSONS-DISEASE, PROGRESSIVE SUPRANUCLEAR PALSY AND HUNTINGTONS-DISEASE", Brain research, 642(1-2), 1994, pp. 327-333
46. HERMANS E; GAILLY P; OCTAVE JN; MALOTEAUX JM; GILLIS JM
    CHARACTERIZATION OF THE AGONIST-INDUCED CALCIUM MOBILIZATION IN TRANSFECTED CHO CELLS EXPRESSING THE RAT NEUROTENSIN RECEPTOR
    Biophysical journal
    
    E. Hermans et al., "CHARACTERIZATION OF THE AGONIST-INDUCED CALCIUM MOBILIZATION IN TRANSFECTED CHO CELLS EXPRESSING THE RAT NEUROTENSIN RECEPTOR", Biophysical journal, 66(2), 1994, pp. 10000052-10000052
47. MALOTEAUX JM; HERMANS E
    AGONIST-INDUCED MUSCARINIC CHOLINERGIC RECEPTOR INTERNALIZATION, RECYCLING AND DEGRADATION IN CULTURED NEURONAL CELLS - CELLULAR MECHANISMSAND ROLE IN DESENSITIZATION
    Biochemical pharmacology
    
    J.M. Maloteaux e E. Hermans, "AGONIST-INDUCED MUSCARINIC CHOLINERGIC RECEPTOR INTERNALIZATION, RECYCLING AND DEGRADATION IN CULTURED NEURONAL CELLS - CELLULAR MECHANISMSAND ROLE IN DESENSITIZATION", Biochemical pharmacology, 47(1), 1994, pp. 77-88
48. HERMANS E; OCTAVE JN; MALOTEAUX JM
    RECEPTOR-MEDIATED INTERNALIZATION OF NEUROTENSIN IN TRANSFECTED CHINESE-HAMSTER OVARY CELLS
    Biochemical pharmacology
    
    E. Hermans et al., "RECEPTOR-MEDIATED INTERNALIZATION OF NEUROTENSIN IN TRANSFECTED CHINESE-HAMSTER OVARY CELLS", Biochemical pharmacology, 47(1), 1994, pp. 89-91
49. HERMANS E; GAILLY P; OCTAVE JN; MALOTEAUX JM
    RAPID DESENSITIZATION OF AGONIST-INDUCED CALCIUM MOBILIZATION IN TRANSFECTED PC12 CELLS EXPRESSING THE RAT NEUROTENSIN RECEPTOR
    Biochemical and biophysical research communications
    
    E. Hermans et al., "RAPID DESENSITIZATION OF AGONIST-INDUCED CALCIUM MOBILIZATION IN TRANSFECTED PC12 CELLS EXPRESSING THE RAT NEUROTENSIN RECEPTOR", Biochemical and biophysical research communications, 198(1), 1994, pp. 400-407
50. HERMANS E; JEANJEAN AP; LADURON PM; OCTAVE JN; MALOTEAUX JM
    POSTNATAL ONTOGENY OF THE RAT-BRAIN NEUROTENSIN RECEPTOR MESSENGER-RNA
    Neuroscience letters
    
    E. Hermans et al., "POSTNATAL ONTOGENY OF THE RAT-BRAIN NEUROTENSIN RECEPTOR MESSENGER-RNA", Neuroscience letters, 157(1), 1993, pp. 45-48
51. NICOLI F; VIONDURY J; MALOTEAUX JM; DELWAIDE C; CONFORTGOUNY S; SCIAKY M; COZZONE PJ
    CSF AND SERUM METABOLIC PROFILE OF PATIENTS WITH HUNTINGTONS-CHOREA -A STUDY BY HIGH-RESOLUTION PROTON NMR-SPECTROSCOPY AND HPLC
    Neuroscience letters
    
    F. Nicoli et al., "CSF AND SERUM METABOLIC PROFILE OF PATIENTS WITH HUNTINGTONS-CHOREA -A STUDY BY HIGH-RESOLUTION PROTON NMR-SPECTROSCOPY AND HPLC", Neuroscience letters, 154(1-2), 1993, pp. 47-51
52. JEANJEAN AP; MESTRE M; MALOTEAUX JM; LADURON PM
    IS THE SIGMA(2) RECEPTOR IN RAT-BRAIN RELATED TO THE K-III ANTIARRHYTHMIC DRUGS( CHANNEL OF CLASS)
    European journal of pharmacology
    
    A.P. Jeanjean et al., "IS THE SIGMA(2) RECEPTOR IN RAT-BRAIN RELATED TO THE K-III ANTIARRHYTHMIC DRUGS( CHANNEL OF CLASS)", European journal of pharmacology, 241(1), 1993, pp. 111-116
53. HOLEMANS S; DEPAERMENTIER F; HORTON RW; CROMPTON MR; KATONA CLE; MALOTEAUX JM
    NMDA GLUTAMATERGIC RECEPTORS, LABELED WITH [H-3] MK-801, IN BRAIN SAMPLES FROM DRUG-FREE DEPRESSED SUICIDES
    Brain research
    
    S. Holemans et al., "NMDA GLUTAMATERGIC RECEPTORS, LABELED WITH [H-3] MK-801, IN BRAIN SAMPLES FROM DRUG-FREE DEPRESSED SUICIDES", Brain research, 616(1-2), 1993, pp. 138-143